Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In
  • Become a Member
  • MB Vision
  • Members
    • Become a Member
      • Types & Rates
    • Benefits
      • Savings and Rewards
    • Member News
    • Member Events
    • Career Center
    • Directory
    • Pay Company Dues
    • FAQs
  • Events
    • Upcoming
    • Types of Events
    • Sponsorship Opportunities
    • The State of Possible Conference
    • Align Summit
    • Member Events
  • Innovation
    • About
    • Drive
      • Application
      • Alumni
      • Partners – MassBio
      • Partners – SCbio
      • Get Involved
      • FAQs
    • CEO & Founder Link
    • Align Summit
    • Partnering
    • Sponsorship Opportunities
  • Savings
    • MassBioEdge
  • Conference Center
    • About MassBioHub
    • Packages & Special Offers
    • Venue Specifications
    • Reserve Today
  • Policy & Advocacy
    • Policy & Advocacy Efforts
    • Diversity, Equity, and Inclusion
      • DEI Report
      • Resource Center
      • Open Letter 2.0
      • Bioversity
    • Economic Development
      • BioReady® Communities
    • Workforce Development
      • Bioversity
    • Vision 2030
    • This is the place.
    • Industry Reports
      • Federal Actions Impact Report
      • Industry Snapshot
      • Biopharma Funding Report
      • DEI Report
      • MA Life Sciences Workforce
  • About
    • About MassBio
    • News & Thought Leadership
    • MB Vision
    • The Studio at Kendall Square
    • Sponsorship Opportunities
    • Staff
    • Board
    • Contact Us
  • Sign In
  • Become a Member
  • MB Vision
Open search form

Member Directory

Click to Open Main Menu

Akebia Therapeutics, Inc.

Life Sciences | Drug Development
Cambridge, MA (857) 998-7068 Website

Overview

We were founded in 2007 to discover and develop novel therapeutic solutions leveraging hypoxia inducible factor—or HIF—biology, a primary regulator involved in multiple major biological pathways.

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.

Global leadership in hypoxia inducible factor (HIF) biology. Dedicated to advancing care for serious disease Pursuing advances across multiple disease states.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • News & Thought Leadership
  • Pay Company Dues
  • Join Today
  • Contact
  • Privacy Policy
  • © 2025 All Rights Reserved